JP7890997B2 - がん、自己免疫及び炎症性障害の治療に有用な三環式化合物 - Google Patents

がん、自己免疫及び炎症性障害の治療に有用な三環式化合物

Info

Publication number
JP7890997B2
JP7890997B2 JP2023545277A JP2023545277A JP7890997B2 JP 7890997 B2 JP7890997 B2 JP 7890997B2 JP 2023545277 A JP2023545277 A JP 2023545277A JP 2023545277 A JP2023545277 A JP 2023545277A JP 7890997 B2 JP7890997 B2 JP 7890997B2
Authority
JP
Japan
Prior art keywords
cancer
malt1
pharmaceutically acceptable
protein
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023545277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024505890A (ja
JP2024505890A5 (enExample
Inventor
ピーター ハーム ボス，
シェルビー エラリー，
シュル フェン，
ジアイェ グオ，
ゴラン クリロフ，
モーガン ローレンツ，
ジェ ニエ，
アンドリュー プラチェック，
ハイフェン タン，
リニー トルゾス，
マイケル トルゾス，
Original Assignee
シュレーディンガー， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シュレーディンガー， インコーポレイテッド filed Critical シュレーディンガー， インコーポレイテッド
Publication of JP2024505890A publication Critical patent/JP2024505890A/ja
Publication of JP2024505890A5 publication Critical patent/JP2024505890A5/ja
Application granted granted Critical
Publication of JP7890997B2 publication Critical patent/JP7890997B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5428—IL-10
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023545277A 2021-01-26 2022-01-25 がん、自己免疫及び炎症性障害の治療に有用な三環式化合物 Active JP7890997B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163141682P 2021-01-26 2021-01-26
US63/141,682 2021-01-26
US202163145344P 2021-02-03 2021-02-03
US63/145,344 2021-02-03
US202163276064P 2021-11-05 2021-11-05
US63/276,064 2021-11-05
PCT/US2022/013671 WO2022164789A1 (en) 2021-01-26 2022-01-25 Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disoders

Publications (3)

Publication Number Publication Date
JP2024505890A JP2024505890A (ja) 2024-02-08
JP2024505890A5 JP2024505890A5 (enExample) 2025-02-04
JP7890997B2 true JP7890997B2 (ja) 2026-07-15

Family

ID=80349693

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023545277A Active JP7890997B2 (ja) 2021-01-26 2022-01-25 がん、自己免疫及び炎症性障害の治療に有用な三環式化合物

Country Status (4)

Country Link
US (1) US12667572B2 (enExample)
EP (1) EP4284804A1 (enExample)
JP (1) JP7890997B2 (enExample)
WO (1) WO2022164789A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118562950A (zh) * 2021-07-09 2024-08-30 广州恩迈生物科技有限公司 Ifp35和/或nmi在诊治系统性红斑狼疮中的应用
WO2023051759A1 (zh) * 2021-09-30 2023-04-06 上海拓界生物医药科技有限公司 三环化合物及其制备方法
JP2025524002A (ja) * 2022-07-22 2025-07-25 シュレーディンガー， インコーポレイテッド 環式化合物及びそれを使用する方法
EP4638458A1 (en) * 2022-12-23 2025-10-29 Janssen Pharmaceutica NV Malt1 inhibitors
CN122003418A (zh) * 2023-09-11 2026-05-08 薛定谔公司 作为malt1抑制剂的环戊并[e]吡唑并[1,5-a]嘧啶衍生物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009108827A1 (en) 2008-02-29 2009-09-03 Wyeth Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof
JP2018520992A (ja) 2015-05-05 2018-08-02 バイエル ファーマ アクチエンゲゼルシャフト アミドで置換されているシクロヘキサン誘導体
WO2018226150A1 (en) 2017-06-05 2018-12-13 Medivir Aktiebolag Pyrazolopyrimidine as malt-1 inhibitors

Family Cites Families (300)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1296940C (en) 1986-06-12 1992-03-10 Noriyuki Inoue Process for the formation of direct positive images
JPS6396652A (ja) 1986-10-13 1988-04-27 Fuji Photo Film Co Ltd 感光材料
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
EP0361341A3 (en) 1988-09-28 1991-07-03 Miles Inc. Therapeutics for aids based on inhibitors of hiv protease
EP0423693B1 (en) 1989-10-16 1997-04-09 Fuji Photo Film Co., Ltd. Silver halide color photographic material
JPH03246540A (ja) 1989-11-07 1991-11-01 Fuji Photo Film Co Ltd 直接ポジカラー写真感光材料
JP2864262B2 (ja) 1990-01-31 1999-03-03 富士写真フイルム株式会社 ハロゲン化銀カラー反転写真感光材料
US5164288A (en) 1990-05-29 1992-11-17 Eastman Kodak Company Photographic element containing pyrazoloazole coupler and oxidized developer competitor
DE4110487A1 (de) 1991-03-13 1992-09-17 Agfa Gevaert Ag Farbfotografisches aufzeichnungsmaterial zur herstellung farbiger bilder
CH681806A5 (enExample) 1991-03-19 1993-05-28 Ciba Geigy Ag
US5213897A (en) 1991-04-03 1993-05-25 Elf Atochem North America, Inc. Epoxy resins containing bound light stabilizing groups
JP3190431B2 (ja) 1991-07-01 2001-07-23 三菱化学株式会社 ケトン誘導体
AU646966B2 (en) 1991-08-23 1994-03-10 Takeda Chemical Industries Ltd. 2-piperazinone compounds, their production and use
JPH07502511A (ja) 1991-12-20 1995-03-16 グラクソ、インコーポレーテッド ５‐α‐テストステロンレダクターゼ阻害剤
JP2886388B2 (ja) 1992-04-20 1999-04-26 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
US5302589A (en) 1992-08-07 1994-04-12 Glaxo, Inc. Heterocyclic inhibitors of 5-α-testosterone reductase
AP459A (en) 1992-12-18 1996-02-14 Glaxo Wellcome Inc Substituted 6-azaandrostenones.
JPH06192199A (ja) 1992-12-25 1994-07-12 Mitsubishi Kasei Corp ケトン誘導体
US5804560A (en) 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5863902A (en) 1995-01-06 1999-01-26 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
DE19529604A1 (de) 1995-08-11 1997-02-13 Bayer Ag Endoparasitizide Mittel auf Basis von Didepsipeptiden, neue Didepsipeptide und ein Verfahren zu ihrer Herstellung
EP0765660A3 (en) 1995-09-28 1998-09-23 Takeda Chemical Industries, Ltd. Microcapsules comprising 2-piperazinone-1-acetic acid compounds
DE19538960A1 (de) 1995-10-19 1997-04-24 Bayer Ag 4a,5a,8a,8b-Tetrahydro-6H-pyrrolo [3',4':4,5] furo [3,2-b] pyridin-6,8(7H)-dion Derivate zur Bekämpfung von Endoparasiten, Verfahren zu ihrer Herstellung
US5747235A (en) 1996-01-26 1998-05-05 Eastman Kodak Company Silver halide light sensitive emulsion layer having enhanced photographic sensitivity
US5780484A (en) 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
AU6013998A (en) 1996-12-30 1998-07-31 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
ZA98825B (en) 1997-02-27 1998-10-19 Guilford Pharm Inc Method of using neurotrophic carbamates and ureas
GB2323842A (en) 1997-04-04 1998-10-07 Ferring Bv Pyridine derivatives
WO1998047523A1 (en) 1997-04-18 1998-10-29 Cephalon Inc. Peptidyl-2-amino-1-hydroxyalkanesulfonic acid cysteine protease inhibitors
US6316429B1 (en) 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
DE19719839A1 (de) 1997-05-12 1998-11-19 Bayer Ag 6-Substituierte 1,2,4a,5a,8a,8b-Hexahydro- und 1,2,3,4,4a,5a,8a,8b-Oktahydro-6H-pyrrolo/3',4':4,5/furo/3,2-b/pyrid-8(7H)-on Derivate und ihre Verwendung zur Bekämpfung von Endoparasiten
ATE318841T1 (de) 1997-05-29 2006-03-15 Merck & Co Inc Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren
US5945441A (en) 1997-06-04 1999-08-31 Gpi Nil Holdings, Inc. Pyrrolidine carboxylate hair revitalizing agents
JP2001523711A (ja) 1997-11-24 2001-11-27 メルク エンド カムパニー インコーポレーテッド 細胞接着阻害薬としての環状アミノ酸誘導体
EP1083875A1 (en) 1998-06-03 2001-03-21 GPI NIL Holdings, Inc. Small molecule carbamate or urea hair growth compositions and uses
WO2000008015A2 (en) 1998-08-07 2000-02-17 Applied Research Systems Ars Holding N.V. Fsh mimetics for the treatment of infertility
GB9819384D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
CN1332726A (zh) 1998-11-02 2002-01-23 卫福有限公司 吡咯烷化合物及其药物用途
AUPP818099A0 (en) 1999-01-14 1999-02-11 Fujisawa Pharmaceutical Co., Ltd. New n-containing heterocyclic compounds
JP2000221631A (ja) 1999-01-28 2000-08-11 Fuji Photo Film Co Ltd 熱現像写真感光材料
WO2000046193A2 (en) 1999-02-03 2000-08-10 Schering Aktiengesellschaft Ether derivatives having neuronal activity
AU3221300A (en) 1999-02-03 2000-08-25 Schering Aktiengesellschaft Carboxylic acid derivatives, process for their preparation and their use as rotamase enzyme activity inhibitors
US6284779B1 (en) 1999-02-03 2001-09-04 Schering Aktiiengesellschaft Heteroaromatic compounds
AU3246600A (en) 1999-03-01 2000-09-21 Elan Pharmaceuticals, Inc. Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 receptor antagonists
ATE269907T1 (de) 1999-04-09 2004-07-15 Tufts College Methoden und reagentien zur bestmmung der enzym- substatspezifität und damit verbundene anwendungen
US6344358B1 (en) 1999-05-28 2002-02-05 Fujisawa Pharmaceutical Co., Ltd. Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property
US6617426B1 (en) 1999-06-22 2003-09-09 Merck & Co Inc Cysteinyl protease inhibitors
WO2001002376A1 (en) 1999-07-06 2001-01-11 Vertex Pharmaceuticals Incorporated Amino-alkyl derivatives
US20050065339A1 (en) 1999-07-06 2005-03-24 Harbeson Scott L. Amino-alkyl derivatives
JP2003507376A (ja) 1999-08-18 2003-02-25 シエーリング アクチエンゲゼルシャフト 神経活性を示すピペリジンおよびピロリジン誘導体
EP1254901A4 (en) 2000-01-26 2003-03-05 Ono Pharmaceutical Co 5-CHAIN CYCLIC COMPOUNDS, CONTAINING NITROGEN, AND MEDICINAL PRODUCTS CONTAINING THE SAME AS ACTIVE INGREDIENTS
KR20030005230A (ko) 2000-03-21 2003-01-17 더 프록터 앤드 갬블 캄파니 Ｎ-치환된 메탈로프로테아제 저해제를 함유하는 탄소환식측쇄
WO2001070682A2 (en) 2000-03-21 2001-09-27 The Procter & Gamble Company Carbocyclic side chain containing metalloprotease inhibitors
PL357250A1 (en) 2000-03-21 2004-07-26 The Procter & Gamble Company Heterocyclic side chain containing metalloprotease inhibitors
EP1268434A1 (en) 2000-04-03 2003-01-02 Bristol-Myers Squibb Pharma Company Cyclic lactams as inhibitors of a-beta protein production
US20020032262A1 (en) 2000-04-24 2002-03-14 Jinfang Zhang 2-aminoarylmethylamine solid support templated for preparation of highly functionalized heterocycle compounds
EP2289887A3 (en) 2000-06-30 2011-07-06 Seikagaku Corporation Epoxycarboxylic acid amides, azides and amino alcohols and processes for preparation of alpha-keto amides by using them
CA2430808A1 (en) 2000-12-18 2002-06-27 Eli Lilly And Company Cycloalkylfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
EP1219305A1 (en) 2000-12-27 2002-07-03 Bayer Aktiengesellschaft Conjugates of integrin receptor antagonists and a cytostatic agent having specifically cleavable linking units
AU2002226674B2 (en) 2000-12-28 2007-03-22 Ono Pharmaceutical Co., Ltd. Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient
WO2002060426A2 (en) 2001-01-03 2002-08-08 President And Fellows Of Harvard College Compounds regulating cell proliferation and differentiation
CA2447999C (en) 2001-05-23 2011-04-26 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US20040204368A1 (en) 2001-05-31 2004-10-14 Kazuyuki Ohmoto Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient
WO2003007888A2 (en) 2001-07-20 2003-01-30 Adipogenix, Inc. Fat accumulation-modulating compounds
EP1438044A1 (en) 2001-10-19 2004-07-21 Transtech Pharma, Inc. Bis-heteroaryl alkanes as therapeutic agents
CA2476665A1 (en) 2002-02-19 2003-08-28 Pharmacia Corporation Tricyclic pyrazole derivatives for the treatment of inflammation
DE60336901D1 (de) 2002-03-07 2011-06-09 X Ceptor Therapeutics Inc Chinazolinon modulatoren von nukleinrezeptoren
WO2004020584A2 (en) 2002-08-27 2004-03-11 Bristol-Myers Squibb Company Antagonists of chemokine receptors
WO2004031145A2 (en) 2002-10-02 2004-04-15 Bristol-Myers Squibb Company Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor xa inhibitors
AU2003300883A1 (en) 2002-12-12 2004-07-09 Cytovia, Inc. Substituted 1-benzoyl-3-cyano-pyrrolo(1,2-a)quinolines
CA2512000C (en) 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
EP1591120A4 (en) 2003-01-28 2009-06-10 Takeda Chemical Industries Ltd RECEPTOR AGONISTS
JP2004245959A (ja) 2003-02-12 2004-09-02 Fuji Photo Film Co Ltd 黒白熱現像感光材料
ES2325440T3 (es) 2003-02-20 2009-09-04 Smithkline Beecham Corporation Compuestos de pirimidina.
WO2005009949A2 (en) 2003-06-30 2005-02-03 Merck & Co., Inc. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
US7825136B2 (en) 2003-07-10 2010-11-02 Vertex Pharmaceuticals Incorporated Potentiators of antibacterial activity
EP1668009A1 (en) 2003-09-26 2006-06-14 Rigel Pharmaceuticals, Inc. Hcv inhibitors and methods of using them
JP2007514648A (ja) 2003-10-24 2007-06-07 エーザイ株式会社 Ｔｏｌｌ−ｌｉｋｅｒｅｃｅｐｔｏｒ２に関連する疾患及び状態を治療するための化合物及び方法
WO2005047899A2 (en) 2003-11-07 2005-05-26 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
WO2005046588A2 (en) 2003-11-07 2005-05-26 Cytokinetics, Inc. Compounds, compositions, and methods
EP1692112A4 (en) 2003-12-08 2008-09-24 Cytokinetics Inc COMPOUNDS, COMPOSITIONS, AND METHODS
CA2555227A1 (en) 2004-02-10 2005-08-25 Janssen Pharmaceutica, N.V. Pyridazinone ureas as antagonists of .alpha.4 integrins
WO2005099363A2 (en) 2004-03-26 2005-10-27 Whitehead Institute For Biomedical Research Methods of diagnosing, preventing and treating cancer metastasis
MXPA06011658A (es) 2004-05-14 2006-12-14 Pfizer Prod Inc Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
SE0401539D0 (sv) 2004-06-15 2004-06-15 Astrazeneca Ab New compounds
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
EP1807399A2 (en) 2004-10-19 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Indole and benzimidazole derivatives
FR2878528B1 (fr) 2004-11-29 2008-05-16 Aventis Pharma Sa 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation
US20060217370A1 (en) 2005-02-18 2006-09-28 Ethan Burstein Compounds useful for the treatment and prevention of pain and screening methods therefor
AR053713A1 (es) 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
WO2006135627A2 (en) 2005-06-10 2006-12-21 Merck & Co., Inc. Inhibitors of akt activity
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
ES2401661T3 (es) 2005-08-02 2013-04-23 Vertex Pharmaceuticals Incorporated Inhibidores de serina proteasas
CA2630234A1 (en) 2005-11-23 2007-05-31 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
BRPI0619733A2 (pt) 2005-12-12 2011-10-11 Genelabs Tech Inc compostos antivirais de n-(anel aromático de 6 membros)-amido
US20070208001A1 (en) 2006-03-03 2007-09-06 Jincong Zhuo Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
JP2007256545A (ja) 2006-03-23 2007-10-04 Konica Minolta Holdings Inc 表示素子
ZA200808966B (en) 2006-03-27 2010-03-31 Nerviano Medical Sciences Srl Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors
JP2008033083A (ja) 2006-07-31 2008-02-14 Konica Minolta Holdings Inc 表示素子
WO2008046082A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of heterocyclic compounds as therapeutic agents
JP2008122829A (ja) 2006-11-15 2008-05-29 Konica Minolta Holdings Inc 表示素子
WO2008070039A2 (en) 2006-12-01 2008-06-12 The Research Foundation Of State University Of New York 3 beta-hydroxysteroid dehydrogenase inhibitors
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
RU2009122670A (ru) 2006-12-21 2011-01-27 Плекссикон, Инк. (Us) Соединения и способы для модуляции киназ и показания к их применению
DE202008018253U1 (de) 2007-02-22 2012-05-21 Beiersdorf Ag Kosmetische und pharmazeutische Anwendungen von N-Acethylhydroxyprolin
JP2008224717A (ja) 2007-03-08 2008-09-25 Konica Minolta Holdings Inc 表示素子
JPWO2008146674A1 (ja) 2007-05-29 2010-08-19 コニカミノルタホールディングス株式会社 表示素子
JP2010533158A (ja) 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ 化合物類−９４５
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
BRPI0814441A2 (pt) 2007-07-19 2015-07-14 Schering Corp Compostos de amida heterocíclica como inibidores de proteína cinase
JPWO2009013976A1 (ja) 2007-07-20 2010-09-30 コニカミノルタホールディングス株式会社 表示素子
JP5532923B2 (ja) 2007-08-07 2014-06-25 コニカミノルタ株式会社 表示素子
JP2009053580A (ja) 2007-08-29 2009-03-12 Konica Minolta Holdings Inc 表示素子
JP5458484B2 (ja) 2007-09-18 2014-04-02 コニカミノルタ株式会社 表示素子
JP2009075204A (ja) 2007-09-19 2009-04-09 Konica Minolta Holdings Inc 表示素子
JP2009103964A (ja) 2007-10-24 2009-05-14 Konica Minolta Holdings Inc 表示素子
WO2009060694A1 (ja) 2007-11-09 2009-05-14 Konica Minolta Holdings, Inc. 表示素子
EP2222326B2 (en) 2007-11-21 2015-02-25 Vib Vzw Inhibitors of malt1 proteolytic activity and uses thereof
EP2215091B1 (en) 2007-12-04 2016-03-30 Nerviano Medical Sciences S.r.l. Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
EP2078713A1 (en) 2007-12-28 2009-07-15 QuoNova GmbH Inhibitors of biofilm formation of gram-positive and gram-negative bacteria
JP2009163177A (ja) 2008-01-10 2009-07-23 Konica Minolta Holdings Inc 表示素子
WO2009098928A1 (ja) 2008-02-06 2009-08-13 Konica Minolta Holdings, Inc. 表示素子
WO2009116352A1 (ja) 2008-03-18 2009-09-24 コニカミノルタホールディングス株式会社 表示素子
WO2009119140A1 (ja) 2008-03-26 2009-10-01 コニカミノルタホールディングス株式会社 表示素子
EP2254886B1 (en) 2008-03-28 2016-05-25 Nerviano Medical Sciences S.r.l. 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2009140464A1 (en) 2008-05-16 2009-11-19 Ligand Pharmaceuticals, Inc. Methods of administration of thrombopoietin mimetic compounds
US8158636B2 (en) 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JP2009276715A (ja) 2008-05-19 2009-11-26 Konica Minolta Holdings Inc 表示素子
PE20091846A1 (es) 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
AU2009248774B2 (en) 2008-05-23 2012-05-31 Novartis Ag Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
CN104530052A (zh) 2008-06-10 2015-04-22 普莱希科公司 用于激酶调节的5h-吡咯[2,3-b]吡嗪衍生物和其适应症
WO2009150947A1 (ja) 2008-06-10 2009-12-17 コニカミノルタホールディングス株式会社 表示素子
JP2010020149A (ja) 2008-07-11 2010-01-28 Konica Minolta Holdings Inc 表示素子の製造方法
EP2349484A2 (en) 2008-07-15 2011-08-03 Novartis AG Heteroaryl derivatives as dgat1 inhibitors
JPWO2010010793A1 (ja) 2008-07-23 2012-01-05 コニカミノルタホールディングス株式会社 表示素子
US20110019265A1 (en) 2008-07-24 2011-01-27 Akihito Hisamitsu Display element and method of forming porous layer in display element
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
CN102186822A (zh) 2008-08-29 2011-09-14 顶标公司 新脲和硫脲衍生物
US8394802B2 (en) 2008-09-19 2013-03-12 Nerviano Medical Sciences S.R.L. 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one derivatives for the modulation of the activity of protein kinases
JP2010072517A (ja) 2008-09-22 2010-04-02 Konica Minolta Holdings Inc 表示素子の製造方法
JP2010085572A (ja) 2008-09-30 2010-04-15 Konica Minolta Holdings Inc 電気化学表示素子
JP2010097043A (ja) 2008-10-17 2010-04-30 Konica Minolta Holdings Inc 表示素子
JP2010117407A (ja) 2008-11-11 2010-05-27 Konica Minolta Holdings Inc 表示素子
JP2010117408A (ja) 2008-11-11 2010-05-27 Konica Minolta Holdings Inc 表示素子
JP2010117405A (ja) 2008-11-11 2010-05-27 Konica Minolta Holdings Inc 表示素子
JP2010117409A (ja) 2008-11-11 2010-05-27 Konica Minolta Holdings Inc 表示素子
JP2010117406A (ja) 2008-11-11 2010-05-27 Konica Minolta Holdings Inc 表示素子
WO2010056631A1 (en) 2008-11-12 2010-05-20 Schering Corporation Inhibitors of fatty acid binding protein (fabp)
US8729077B2 (en) 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
RU2016116516A (ru) 2008-12-08 2018-12-07 Мандифарма Интернэшнл Корпорейшн Лимитед Композиции ингибиторов тирозинкиназных рецепторов белков
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
AU2009330821B2 (en) 2008-12-24 2015-06-11 Bial - Portela & Ca, S.A. Pharmaceutical compounds
JP2012051804A (ja) 2008-12-26 2012-03-15 Kyoto Univ Ｅｇ５阻害剤
JP2010164683A (ja) 2009-01-14 2010-07-29 Konica Minolta Holdings Inc 表示素子
JP2010164804A (ja) 2009-01-16 2010-07-29 Konica Minolta Holdings Inc 表示素子及び表示素子の製造方法
JP2010164861A (ja) 2009-01-17 2010-07-29 Konica Minolta Holdings Inc 表示素子
US20110319416A1 (en) 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
EP2396004A4 (en) 2009-02-11 2012-07-25 Reaction Biology Corp SELECTIVE KINASE HEMMER
JP2010204614A (ja) 2009-03-06 2010-09-16 Konica Minolta Holdings Inc 表示素子
WO2010111527A1 (en) 2009-03-26 2010-09-30 Plexxikon, Inc. Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
EP2414348B1 (en) 2009-04-03 2013-11-20 Merck Sharp & Dohme Corp. Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders
JP2010256524A (ja) 2009-04-23 2010-11-11 Konica Minolta Holdings Inc 表示素子
JP2010256602A (ja) 2009-04-24 2010-11-11 Konica Minolta Holdings Inc 表示素子
EP3045457B1 (en) 2009-06-15 2018-05-09 Nerviano Medical Sciences S.r.l. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
JP2011008081A (ja) 2009-06-26 2011-01-13 Konica Minolta Holdings Inc 表示素子
UY32826A (es) 2009-08-04 2011-02-28 Takeda Pharmaceutical Compuestos heterocíclicos
WO2011020913A2 (en) 2009-08-21 2011-02-24 Pharma Mar, S.A. Cyclodepsipeptide antiviral compounds
JP2011048234A (ja) 2009-08-28 2011-03-10 Konica Minolta Holdings Inc 表示素子
JP2011053396A (ja) 2009-09-01 2011-03-17 Konica Minolta Holdings Inc 表示素子
AU2010295622A1 (en) 2009-09-16 2012-05-10 Cylene Pharmaceuticals, Inc. Tricyclic compounds and pharmaceutical uses thereof
EP2485735B1 (en) 2009-10-08 2015-07-29 Merck Sharp & Dohme Corp. Inhibitors of fatty acid binding protein (fabp)
WO2011092120A1 (en) 2010-01-29 2011-08-04 Nerviano Medical Sciences S.R.L. 6,7- dihydroimidazo [1,5-a] pyrazin-8 (5h) - one derivatives as protein kinase modulators
ES2594927T3 (es) 2010-02-18 2016-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos para prevenir las metástasis cancerosas
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
WO2012021401A1 (en) 2010-08-12 2012-02-16 Novozymes, Inc. Compositions comprising a polypeptide having cellulolytic enhancing activity and a bicyclic compound and uses thereof
BR112013005223A2 (pt) 2010-09-03 2016-05-03 Bayer Ip Gmbh "pirimidinonas e dihidropirimidinonas fusionadas substituídas."
EP2668188B1 (en) 2011-01-26 2016-05-18 Nerviano Medical Sciences S.r.l. Tricyclic derivatives, process for their preparation and their use as kinase inhibitors
US8975267B2 (en) 2011-01-26 2015-03-10 Nerviano Medical Sciences S.R.L. Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors
PE20141360A1 (es) 2011-02-07 2014-10-13 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos.
US9199979B2 (en) 2011-02-24 2015-12-01 Nerviano Medical Sciences S.R.L. Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
US9284298B2 (en) 2011-04-11 2016-03-15 Nerviano Medical Sciences S.R.L. Pyrazolyl-pyrimidine derivatives as kinase inhibitors
RU2621732C2 (ru) 2011-04-19 2017-06-07 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Замещенные пиримидинилпирролы, активные в качестве ингибиторов киназы
CN103491775A (zh) 2011-04-21 2014-01-01 巴斯夫欧洲公司 3,4-二取代的吡咯-2,5-二酮及其作为杀真菌剂的用途
WO2012154888A1 (en) 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Compounds for treating protein folding disorders
EA023579B1 (ru) 2011-05-12 2016-06-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Замещенные производные индазола, активные в качестве ингибиторов киназы
US20150105548A1 (en) 2011-05-26 2015-04-16 Abbvie Inc Anti-viral compounds
EP2736514B1 (en) 2011-07-28 2017-10-18 Nerviano Medical Sciences S.r.l. Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors
EP2761300A4 (en) 2011-09-27 2015-12-02 Univ Michigan Recurrent genital fusion in breast cancer
ES2660265T3 (es) 2011-10-07 2018-03-21 Nerviano Medical Sciences S.R.L. Derivados de 3,4-dihidropirrolo[1,2-a]pirazin-1(2h)-ona 4-alquil-sustituidos como inhibidores de cinasa
WO2013050446A1 (en) 2011-10-07 2013-04-11 Nerviano Medical Sciences S.R.L. SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASES INHIBITORS
EP2788450B1 (en) 2011-12-06 2017-06-21 Nitto Denko Corporation Wavelength conversion material as encapsulant for solar module systems to enhance solar harvesting efficiency
DE21212055T1 (de) 2011-12-07 2022-08-04 Alnylam Pharmaceuticals, Inc. Biologisch abbaubare lipide zur freisetzung von wirkstoffen
US20140308304A1 (en) 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
WO2013086322A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
TW201331194A (zh) 2011-12-23 2013-08-01 Millennium Pharm Inc 雜芳基化合物及其用途
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CN104640572B (zh) 2012-05-15 2018-04-27 索伦托医疗有限公司 药物偶联物，偶联方法，及其用途
JP6653573B2 (ja) 2012-05-22 2020-02-26 トラスティーズ・オブ・ダートマウス・カレッジ シクロアルカニル［ｂ］インドール、シクロアルカニル［ｂ］ベンゾフラン、シクロアルカニル［ｂ］ベンゾチオフェンを合成するための方法、化合物および使用の方法
NZ703495A (en) 2012-07-11 2018-02-23 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
CN104428392B (zh) 2012-07-13 2017-05-31 默克专利有限公司 金属络合物
EP2690094A1 (en) 2012-07-24 2014-01-29 Centro Atlantico del Medicamento S.A (Ceamed, S.A) Fused quinonic compounds
US20150197503A1 (en) 2012-07-27 2015-07-16 Bial-Portela & Cª, S.A. Process for the synthesis of substituted urea compounds
CN104507923B (zh) 2012-08-02 2018-02-09 内尔维阿诺医学科学有限公司 作为激酶抑制剂的取代的吡咯类活性剂
EP2917214B1 (en) 2012-11-07 2019-08-28 Nerviano Medical Sciences S.r.l. Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors
WO2014078733A1 (en) 2012-11-16 2014-05-22 The Regents Of The University Of California Pictet-spengler ligation for protein chemical modification
MX2015004626A (es) 2012-11-29 2015-07-14 Yeda Res & Dev Metodos para prevenir metastasis de tumor, tratar y pronosticar cancer e identificar agentes que son inhibidores putativos de metastasis.
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
CN105431436B (zh) 2013-05-14 2017-11-28 内尔维阿诺医学科学有限公司 吡咯并[2,3‑d]嘧啶衍生物，它们的制备方法和它们作为激酶抑制剂的用途
RU2015149937A (ru) 2013-05-30 2017-07-06 Плексксикон Инк. Соединения для модулирования киназы и показания к их применению
WO2015017528A1 (en) 2013-07-30 2015-02-05 Blueprint Medicines Corporation Pik3c2g fusions
EP3628749A1 (en) 2013-07-30 2020-04-01 Blueprint Medicines Corporation Ntrk2 fusions
WO2015023898A1 (en) 2013-08-14 2015-02-19 Rqx Pharmaceuticals, Inc. Linear peptide antibiotcs
EP2857550A1 (en) 2013-10-02 2015-04-08 Basf Se Amine precursors for depositing graphene
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
MX365614B (es) 2013-10-17 2019-06-07 Blueprint Medicines Corp Composiciones utiles para tratar trastornos relacionados con kit.
PT3395814T (pt) 2013-10-25 2022-07-27 Blueprint Medicines Corp Inibidores do recetor do fator de crescimento de fibroblastos
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
WO2015112806A2 (en) 2014-01-24 2015-07-30 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
US20170015677A1 (en) 2014-03-31 2017-01-19 Boston Biomedical, Inc. New tricyclic quinone derivative
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015161274A1 (en) 2014-04-18 2015-10-22 Blueprint Medicines Corporation Pik3ca fusions
US20170044621A1 (en) 2014-04-18 2017-02-16 Blueprint Medicines Corporation Met fusions
JP6545197B2 (ja) 2014-05-28 2019-07-17 ノバルティス アーゲー 新規なピラゾロピリミジン誘導体およびｍａｌｔ１阻害剤としてのその使用
EP3155131B1 (en) 2014-06-10 2020-02-12 Blueprint Medicines Corporation Raf1 fusions
WO2015191667A1 (en) 2014-06-10 2015-12-17 Blueprint Medicines Corporation Pkn1 fusions
US10370724B2 (en) 2014-07-17 2019-08-06 Blueprint Medicines Corporation PRKC fusions
EP3169804B3 (en) 2014-07-17 2019-09-18 Blueprint Medicines Corporation Fgr fusions
WO2016011144A1 (en) 2014-07-17 2016-01-21 Blueprint Medicines Corporation Tert fusions
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
EP3218378B1 (en) 2014-11-14 2020-01-08 Nerviano Medical Sciences S.r.l. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
US20170356052A1 (en) 2014-11-18 2017-12-14 Blueprint Medicines Corporation Prkacb fusions
CN107001337B (zh) 2015-01-13 2021-05-04 诺华股份有限公司 作为血管紧张素ii型拮抗剂的吡咯烷衍生物
WO2016131380A1 (en) 2015-02-16 2016-08-25 Shanghai De Novo Pharmatech Co.,Ltd. Fused-ring compounds, pharmaceutical composition and uses thereof
WO2016140189A1 (ja) 2015-03-04 2016-09-09 国立大学法人京都大学 光学活性α－フルオロアミノ酸化合物又はその塩の製造方法
WO2016201319A1 (en) 2015-06-10 2016-12-15 The Broad Institute Inc. Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia
EP3805213A3 (en) 2015-06-18 2021-06-09 Nippon Soda Co., Ltd. 1-(2-(ethylsulfonyl)-phenyl)-4-(phenyl)-1h-1,2,3-triazole and 4-(2-(ethylsulfonyl)-phenyl)-1-(phenyl)-1h-1,2,3-triazole and related compounds derivatives as pesticides
EP3313846B1 (en) 2015-06-25 2020-05-06 Promega Corporation Thienopyrrole compounds and uses thereof as inhibitors of oplophorus-derived luciferases
WO2017040304A1 (en) 2015-08-28 2017-03-09 Cornell University Malt1 inhibitors and uses thereof
EP3374361A1 (en) 2015-11-13 2018-09-19 Novartis AG Novel pyrazolo pyrimidine derivatives
TWI725075B (zh) 2015-11-20 2021-04-21 美商Ｒｑｘ製藥公司 巨環廣效抗生素
WO2017106134A1 (en) 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Benzimidazoles and indoles as taro inhibitors
WO2018020474A1 (en) 2016-07-29 2018-02-01 Lupin Limited Substituted thiazolo-pyridine compounds as malt1 inhibitors
CN110087680B (zh) 2016-08-19 2024-03-19 百济神州有限公司 使用包含btk抑制剂的组合产品治疗癌症
CN110023474A (zh) 2016-09-29 2019-07-16 诺维信公司 酶用于洗涤的用途、洗涤方法和器皿洗涤组合物
WO2018129205A1 (en) 2017-01-04 2018-07-12 The Trustees Of Dartmouth College Methods of inhibiting pcsk9
WO2018133845A1 (zh) 2017-01-23 2018-07-26 上海长森药业有限公司 硫脲类、脲类化合物及其用途
EP3576744A1 (en) 2017-02-01 2019-12-11 Medivir Aktiebolag Therapeutic applications of malt1 inhibitors
UA126027C2 (uk) 2017-02-15 2022-08-03 АрКьюЕкс ФАРМАСЬЮТІКЛС, ІНК. Макроциклічні антибіотики широкого спектра
CN108456216B (zh) 2017-02-22 2021-12-28 上海长森药业有限公司 磺酰肼类化合物及其用途
EP3592731A4 (en) 2017-03-08 2020-10-07 Cornell University MALT1 INHIBITORS AND THEIR USES
CN108623587A (zh) 2017-03-24 2018-10-09 中国海洋大学 一种含羰基的胺类化合物及其制备方法和用途
CN108623588A (zh) 2017-03-24 2018-10-09 中国海洋大学 一种含内酰胺的四环衍生物及其制备方法和应用
WO2018210659A1 (en) 2017-05-15 2018-11-22 Basf Se Heteroaryl compounds as agrochemical fungicides
WO2018210658A1 (en) 2017-05-15 2018-11-22 Basf Se Heteroaryl compounds as agrochemical fungicides
CN108948019B (zh) 2017-05-18 2022-07-08 广东东阳光药业有限公司 黏着斑激酶抑制剂及其用途
GB201708451D0 (en) 2017-05-26 2017-07-12 Univ Oxford Innovation Ltd Inhibitors of metallo-beta-lactamases
US11584744B2 (en) 2017-06-23 2023-02-21 University Of Washington Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
WO2019086009A1 (zh) 2017-11-03 2019-05-09 华南农业大学 含氮稠合三环化合物及其作为农林业杀虫剂的应用
EP3710426A4 (en) 2017-11-03 2021-03-24 Bioimics AB ANTI-INFECTIOUS HETEROCYCLIC COMPOUNDS AND THEIR USES
EP3781154A4 (en) 2018-04-04 2022-02-23 Case Western Reserve University COMPOSITIONS AND METHODS FOR TREATMENT OF KIDNEY INJURY
JP7359447B2 (ja) 2018-05-07 2023-10-11 学校法人東京理科大学 硬化性組成物、化合物、塩基変換増殖剤及び硬化物
CN122165747A (zh) 2018-05-14 2026-06-09 易客发有限公司 平版印刷版前体
EP3587112B1 (en) 2018-06-21 2024-04-03 Eco3 Bv A lithographic printing plate precursor
JP7384418B2 (ja) 2018-08-28 2023-11-21 学校法人東京理科大学 硬化性組成物、硬化物、及び硬化物の製造方法
US20210330678A1 (en) 2018-09-05 2021-10-28 Children`S Medical Center Corporation Papd5 inhibitors and methods of use thereof
US20210353627A1 (en) 2018-09-21 2021-11-18 Spectrum Pharmaceuticals, Inc. Novel quinazoline egfr inhibitors
US11891422B2 (en) 2018-11-16 2024-02-06 New York University NEMO coiled coil mimics and methods of using same
WO2020115076A2 (en) 2018-12-03 2020-06-11 The University Court Of The University Of Glasgow Insect control agents
WO2020156022A1 (en) 2019-01-29 2020-08-06 The Hong Kong University Of Science And Technology Methods for enantioselective preparation of chiral tetraarylmethanes
CN111662284B (zh) 2019-03-06 2021-08-10 上海海雁医药科技有限公司 双杂环取代的氧杂螺环衍生物、其制法与医药上的用途
WO2020182188A1 (zh) 2019-03-13 2020-09-17 习峰 取代的杂芳基化合物及其组合物和用途
CN114793437A (zh) 2019-04-30 2022-07-26 Encodia 公司 用于从多肽上切割n端氨基酸的方法和试剂
WO2021085636A1 (ja) 2019-10-30 2021-05-06 学校法人中部大学 アミド反応用反応剤及びそれを用いたアミド化合物の製造方法
EP4069311A1 (en) 2019-12-03 2022-10-12 Debiopharm Research & Manufacturing SA Reactive conjugates
CN115103591B (zh) 2019-12-27 2026-06-19 度勒科特公司 结晶性和液体结晶性25-羟基-胆甾-5-烯-3-硫酸钠及其制备方法
IL294214B2 (en) 2019-12-27 2026-04-01 Schrodinger Inc Cyclic compounds and methods of using same
GEAP202416015A (en) 2019-12-27 2024-04-10 Lupin Ltd Substituted tricyclic compounds
GEP20247590B (en) 2019-12-27 2024-02-12 Tecnimede Sociedade Tecnico Medicinal Sa Antibacterial quinolines
WO2021178362A1 (en) 2020-03-03 2021-09-10 VenatoRx Pharmaceuticals, Inc. Hepatitis b capsid assembly modulators
WO2021201201A1 (ja) 2020-04-03 2021-10-07 インタープロテイン株式会社 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の予防または治療剤および医薬組成物
JP7451765B2 (ja) 2020-05-12 2024-03-18 蘇州阿尓脈生物科技有限公司 Ｃｄｋ阻害剤としてのピリジンアセトアミド系誘導体、その調製方法及び用途
US12606557B2 (en) 2020-05-27 2026-04-21 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Substituted indoles with inhibitory activity
CN116157017A (zh) 2020-06-18 2023-05-23 拜耳公司 作为杀菌剂用于作物保护的3-(哒嗪-4-基)-5,6-二氢-4h-1,2,4-噁二嗪衍生物
CN116113406B (zh) 2020-07-10 2025-08-29 密歇根大学董事会 Gas41抑制剂及其使用方法
US12534479B2 (en) 2020-07-10 2026-01-27 Findcure Biosciences (Zhongshan) Co., Ltd. Triazine compound and composition and use thereof
TW202220958A (zh) 2020-08-07 2022-06-01 美商卡司馬療法公司 Ｔｒｐｍｌ調節劑
CN114075184B (zh) 2020-08-17 2023-05-05 四川大学华西医院 一种用于麻醉的季铵盐类化合物及其制备方法和用途
GB202018412D0 (en) 2020-11-23 2021-01-06 Exscientia Ltd Malt-1 modulators ii
WO2022240541A1 (en) 2021-05-11 2022-11-17 Enanta Pharmaceuticals, Inc. Novel macrocyclic spiropyrrolidine derived antiviral agents
US20240277876A1 (en) 2021-05-20 2024-08-22 The Regents Of The University Of California Pet imaging tracers
JP2025501056A (ja) 2021-12-30 2025-01-17 シャンハイ ハンソー バイオメディカル カンパニー リミテッド 三環系誘導体阻害剤、その製造方法と応用
TW202340198A (zh) 2022-01-28 2023-10-16 大陸商上海齊魯製藥研究中心有限公司 靶向ｍａｌｔ１的蛋白降解化合物、包含其的醫藥組合物及其用途
CN115181049B (zh) 2022-06-01 2023-12-19 郑州玛特瑞斯生物科技有限公司 一种荧光化合物及其制备方法、荧光修饰核苷酸、测序试剂
JP2025524002A (ja) 2022-07-22 2025-07-25 シュレーディンガー， インコーポレイテッド 環式化合物及びそれを使用する方法
CN122003418A (zh) 2023-09-11 2026-05-08 薛定谔公司 作为malt1抑制剂的环戊并[e]吡唑并[1,5-a]嘧啶衍生物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009108827A1 (en) 2008-02-29 2009-09-03 Wyeth Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof
JP2018520992A (ja) 2015-05-05 2018-08-02 バイエル ファーマ アクチエンゲゼルシャフト アミドで置換されているシクロヘキサン誘導体
WO2018226150A1 (en) 2017-06-05 2018-12-13 Medivir Aktiebolag Pyrazolopyrimidine as malt-1 inhibitors

Also Published As

Publication number Publication date
US12667572B2 (en) 2026-06-30
EP4284804A1 (en) 2023-12-06
JP2024505890A (ja) 2024-02-08
US20240148732A1 (en) 2024-05-09
WO2022164789A9 (en) 2023-05-25
WO2022164789A1 (en) 2022-08-04

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250127

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260424

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260603

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260703

R150 Certificate of patent or registration of utility model

Ref document number: 7890997

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150